# A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

> **NCT02207465** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy
- Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT02207465
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-07
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207465, "A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02207465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*